Rhizoma Smilacis Glabrae
Adjuvants include polysorbate 80, sodium hydroxide and glacialacetic acid.
5ml per ampoule
Intravenous injection: 12ml each time mixed with
200ml NaCl injection, once dailyfor 2 -3 consecutive days.
clears heat and disperses lumps
metastatic bone cancer
unresectable primary liver cancer
advanced non-small cell lung cancer
improve the immunologic function
A large of clinical experiments showed that SS+ injection had significant inhibitory effect on the adhesion of tumour cells to vascular endothelial cells. It could maintain the integrality of endothelial cells and block the adhesion of tumour cells to matrix by lowering its permeability, so that reduce the probability of tumour metastasis. In addition, because of its unique mechanism, it can effectively inhibit the proliferative cycle of tumour cells and target, lower the sensitivity of serum TNF alpha and inhibit the occurrence and development of tumours.
Side effects: No obvious general toxic or side effects. Mild stimulation in local administration but with good absorption.
Contraindications: Cautions in severe heart and kidney failure.
Cautions: Use under the directions of doctors.
Effects of Compound SS+ Injection on the Immunologic Function of Patients After Colorectal Cancer Resection
OBJECTIVE: To evaluate the effects of compound SS+(Radix sophorae flavescentis) injection on the immunologic function of patients after colorectal cancer resection.
METHODS: Eighty patients after colorectal cancer resection were randomly divided into two groups: 40 patients in control group were treated with routine chemotherapy including 5-fluorouridine(5-FU),calcium folinate(CF) and oxaliplatin,40 patients in experimental group were treated with the same chemotherapy regime combined with 20 mL·d-1 compound SS+ injection for 10d during chemotherapy. Flow cytometry was used to examine the numbers of T lymphocytes subsets(CD3, CD4+, CD4+/CD8+) and the NK cells in blood samples.
RESULTS: In control group,the numbers of CD3+,CD4+T cells,NK cells and CD4+/CD8+ ratio significantly declined than those before chemotherapy(P0.05) while CD8+T lymphocyte number was increased significantly.In experimental group,there were no significant differences between the numbers of CD3+,CD4+,CD8+T cells,NK cells,and CD4+/CD8+ ratio before and after chemotherapy(P0.05).After chemotherapy,the numbers of CD3+,CD4+T cells,NK cells and CD4+/CD8+ ratio were higher in experimental group than in control group(P0.05),while the number of CD8+T lymphocyte was similar between two groups.
CONCLUSION: Compound SS+ injection can improve the immunologic function of patients receiving chemotherapy after colorectal cancer resection.
Evaluation and Analysis of Drug-Use in Hospitals of China 2009-09; R735.3, CNKI:SUN:YYPF.0.2009-09-025
Enhancing effect of compound Kusheng injection in combination with chemotherapy for patients with advanced non-small cell lung cancer
OBJECTIVE: To explore the enhancing effect of compound Kusheg injection in chemotherapy for patients with stage III and IV non-small cell lung cancer (NSCLC).
METHODS: A total of 286 patients with advanced NSCLC were enrolled in this study. The patients were treated with either compound Kusheng injection in combination with NP (NVB + CBP) chemotherapy (vinorelbine and carboplatin, n = 144), or with NP (NVB + CBP) chemotherapy alone (n = 142). The chemotherapy was performed for 4 cycles of 3 weeks, and the therapeutic efficacy was evaluated every 2 weeks. The following indicators were observed: levels of Hb, WBC, PLT and T cell subpopulations in blood, serum IgG level, short-term efficacy, adverse effects and quality of life.
RESULTS: The gastrointestinal reactions and the myelosuppression in the combination chemotherapy group were alleviated as compared with the chemotherapy alone group, showing a significant difference (P < 0.05). CD(8)(+) cells were markedly declined in the combination chemotherapy group, and the CD(4)(+)/CD(8)(+) ratio showed an elevation trend in the chemotherapy alone group. The KPS scores and serum IgM and IgG levels were higher in the combination chemotherapy group than those in the chemotherapy alone group (P < 0.01 and P < 0.05). The serum lgA levels were not significantly different in the two groups.
CONCLUSION: The compound Kusheng injection plus NP chemotherapy regimen shows better therapeutic effect, reduces adverse effects of chemotherapy and improves the quality of life in patients with stage III and IV NSCLC.
Zhonghua Zhong Liu Za Zhi 32(4):294-7 (2010)
SS+ injection and anti-tumor drugs in inhibiting the growth of human lung cancer cell line
Objective: To study the activities of SS+ injection and anti-tumor drugs on SPCA/I human lung adenocarcinoma cell line.
Methods: Suppression effects of different concentrations of SS+ injection and SS+ injection combined with anti-tumor drugs on lung cancer cells were measured by methyl thiazolyl tetrazolium (MTT) colorimetric assay.
Results: Different concentrations of SS+ injection could inhibit the growth of SPCA/I human lung adenocarcinoma cells and there was a positive correlation between the inhibition rate and the drug concentration. Different concentrations of SS+ injection combined with anti-tumor drugs had higher growth inhibition rate than anti-tumor drugs alone.
Conclusion: SS+ injection has direct growth suppression effect on SPCA/I human lung adenocarcinoma cells and SS+ injection combined with anti-tumor drugs shows a significant synergistic effect on tumor cells.
Journal of Chinese Integrative Medicine: 2008; 6(2): 163-165,
Composite SS+ injection combined with hepatic artery embolism on unresectable primary liver cancer
Objective: It is to observe the effect of composite SS+ injection combined with transcatheter hepatic arterial chemoembolization(TACE) on unresectable primary liver cancer.
Methods: 57 patients with unresectable primary liver cancer were randomly divided into 2 groups.The treatment group with 27 cases was treated by TACE combined with composite SS+ injection,and the control group with 30 cases was treated by TACE alone.The clinical curative effects were observed after treatment in both groups.
Results: 1,2,3 year survival rates of treatment group were 67%,48% and 37% respectively,and those of control group were 53%,37% and 20% respectively.There were significantly differences in both groups(P all0.05).
Conclusion: Combined TACE with composite SS+ injection can increase the efficacy of patients with unresectable primary liver cancer.
Modern Journal of Integrated Traditional Chinese and Western Medicine 2009-12; R735.7, CNKI:SUN:XDJH.0.2009-12-007
Clinical study of treating metastatic bone cancer with radiotherapy and composite SS+ injection
Objective: To explore the methods of synthetic treatment about metastatic bone cancer.
Methods: 60 cases of metastatic bone cancer inpatients at the same stage were assigned to treatment group and control group,30 cases each group.After basic control about two groups metastatic bone cancer with synthetic treatemnt,metastatic bone cancer were treated with 60 Co or 6mv straightline speeder at local extracorporeal radiotherapy of DT 30~40GY three to four weeks,and treatment group were simultaneously continuously treated with composite SS+ injection 20ml+0.9% NS 250ml ivdrip every day.The differences of two groups cases were compared in respect of count of leukocyte and the changes and early therapeulic effects of ALP and survival duration.
Results: In the treatment group the count of leukocyte in 90% cases was at normal range and ALP on the decrease of 100U/L was 53.3%,which were significant beyond those in control group.The CR+PR rate of treatment group and control group was respectively 96.66%(29/30) and 66.66%(20/30)(P0.01).One year survival rate of two groups was no difference,but the survival duration of 4 cases in treatment group was beyond 18 months.
Conclusion: It is a good method of treatment of matstatic bone cancer and effective control of pains with radiotherapy and composite SS+ injection and it has significantly cooperative function,specified clinical significance for the protection of luekocye and the decrease of ALP.
Chinese Journal of Primary Medicine Pharmacy 2004-07; R738.1, CNKI:SUN:ZJCY.0.2004-07-060